ライフサイエンスコーパス: granulomatosis

1 ingham Vasculitis Activity Score for Wegener granulomatosis).

2 and one with toxoplasmosis plus lymphomatoid granulomatosis).

3 and glomerulonephritis (excluding Wegener's granulomatosis).

4 ulomatosis with polyangiitis (GPA, Wegener's granulomatosis).

5 o an initial mistaken diagnosis of Wegener's granulomatosis.

6 d, controlled trial in patients with Wegener granulomatosis.

7 nervous system involvement from lymphomatoid granulomatosis.

8 implicated in the pathogenesis of Wegener's granulomatosis.

9 litis Activity Score, modified for Wegener's granulomatosis.

10 s for clinical care of patients with Wegener granulomatosis.

11 uction agent for severe refractory Wegener's granulomatosis.

12 a role in the etiopathogenesis of Wegener's granulomatosis.

13 such as microscopic polyangiitis and Wegener granulomatosis.

14 the lesions of patients with Langerhans cell granulomatosis.

15 lant recipients and 1 patient with Wegener's granulomatosis.

16 ted patients with limited forms of Wegener's granulomatosis.

17 ing aortitis, atherosclerosis, and Wegener's granulomatosis.

18 leptomeningeal biopsy demonstrated Wegener's granulomatosis.

19 zations among 571 individuals with Wegener's granulomatosis.

20 acy in severe vasculitis or severe Wegener's granulomatosis.

21 hiolitis, NCGN, capillaritis, arteritis, and granulomatosis.

22 th polyangiitis, formerly known as Wegener's granulomatosis.

23 CGN, lung capillaritis and arteritis, but no granulomatosis.

24 with NCGN, lung capillaritis, arteritis and granulomatosis.

25 One of them is Wegener's granulomatosis.

26 osis was suggested to be a type of Wegener's granulomatosis.

27 och-Schonlein purpura, and A1AT in Wegener's granulomatosis.

28 its relevance to the diagnosis of Wegener's granulomatosis.

29 ic forms of damage associated with Wegener's granulomatosis.

30 tant concern for all patients with Wegener's granulomatosis.

31 e of morbidity among patients with Wegener's granulomatosis.

32 lasmic antibodies in patients with Wegener's granulomatosis.

33 NK-cell angiocentric lymphomas (lymphomatoid granulomatosis), 12/19 T-cell anaplastic large-cell lymp

34 a case of hepatosplenic necrotizing sarcoid granulomatosis, a variant form of "classical" sarcoidosi

35 than mature-PR3-ANCA as a measure of Wegener granulomatosis activity.

36 lomatous pathology, which we term "asthmatic granulomatosis." Although identification of this disease

37 d 10,771 hospitalizations included Wegener's granulomatosis among the discharge diagnoses.

38 mics the full spectrum of human lymphomatoid granulomatosis, an EBV-associated malignancy with no eff

39 icacious for treating low-grade lymphomatoid granulomatosis and hence reducing progression to high-gr

40 62-year-old male with a history of Wegener's granulomatosis and immunosuppressive therapy presented w

41 aspects of the care of children with Wegener granulomatosis and microscopic polyangiitis are derived

42 nosis of such types of vasculitis as Wegener granulomatosis and microscopic polyangiitis.

43 scular damage from EBV-positive lymphomatoid granulomatosis and nasal or nasal-type T/natural killer

44 d in patients with EBV-positive lymphomatoid granulomatosis and nasal or nasal-type T/NK-cell lymphom

45 re often in a position to diagnose Wegener's granulomatosis and prevent significant morbidity.

46 hose of ELISA is highly specific for Wegener granulomatosis and related vasculitides even in patients

47 st a familial link between risk of Wegener's granulomatosis and rheumatoid arthritis.

48 ly unexpected associations between Wegener's granulomatosis and the incidence of malignancy, venous t

49 phritis (NCGN), pathogenesis of ANCA-induced granulomatosis and vasculitis outside the kidney has not

50 yclophosphamide for the treatment of Wegener granulomatosis and were followed for 0.5 to 27 years (me

51 th polyangiitis (formerly known as Wegener's granulomatosis) and microscopic polyangiitis.

52 PECAM-1 and it may have a role in Wegener's granulomatosis, and antibodies to HNA-2a frequently caus

53 e useful in preventing relapses in Wegener's granulomatosis, and patients develop fewer infections.

54 Sarcoidosis, Wegener granulomatosis, and pseudorheumatoid nodules must be rul

55 In Europe, Wegener granulomatosis appears to be more common at high latitud

56 systemic lupus erythematosus, and Wegener's granulomatosis are also reported.

57 in the geographic distribution of Wegener's granulomatosis are apparent when analysis consider rates

58 ing patterns of orbital disease in Wegener's granulomatosis are presented.

59 Granulomatous syndromes, such as Wegener's granulomatosis, are defined according to complex criteri

60 icates in the United States listed Wegener's granulomatosis as a cause of death.

61 cribe a patient who presented with Wegener's granulomatosis associated with antineutrophil cytoplasmi

62 New diagnosis of Wegener's granulomatosis at baseline was an independent predictor

63 ated, or relapsed or refractory lymphomatoid granulomatosis at the National Cancer Institute (Nationa

64 roversy has arisen over the eponym Wegener's granulomatosis because of alleged involvement of Friedri

65 temic sclerosis, Takayasu arteritis, Wegener granulomatosis, Behcet syndrome, and transplant arterios

66 The syndrome resembles Wegener's granulomatosis both clinically and histologically.

67 ficiency and cutaneous Staphylococcus aureus granulomatosis (botryomycosis) in a cohort of related Sw

68 events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known.

69 rmingham Vasculitis Activity Score/Wegener's Granulomatosis (BVAS/WG)=0 off prednisone.

70 gham Vasculitis Activity Score for Wegener's granulomatosis [BVAS/WG] score of 0) at month 6.

71 This case illustrates that Wegener's granulomatosis can cause chronic meningitis.

72 ryllium is associated with a human pulmonary granulomatosis characterized by an accumulation of CD4(+

73 eryllium disease (CBD) is a hypersensitivity granulomatosis characterized by beryllium hypersensitivi

74 Study of other vasculitides, such as Wegener granulomatosis, Churg-Strauss syndrome, and microscopic

75 ain systemic conditions, including Wegener's granulomatosis, Cogan's syndrome, polyarteritis nodosa,

76 with systemic lupus erythematosis or Wegener granulomatosis did not differ from patients without cGVH

77 omarker for the autoimmune disease Wegener's granulomatosis, diluted up to 10(7)-fold in 1% human ser

78 the development of eosinophilic polyangiitis granulomatosis (EGPA) in a young girl being treated for

79 During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-contro

80 lignancies was observed during the Wegener's Granulomatosis Etanercept Trial (WGET), which included 1

81 We evaluated data from the Wegener's Granulomatosis Etanercept Trial.

82 udy used the BVAS/WG data from the Wegener's Granulomatosis Etanercept Trial.

83 Although studies of Wegener's granulomatosis frequently focus on controlling disease a

84 dosa, hypersensitivity vasculitis, Wegener's granulomatosis, giant cell arteritis and Takayasu's arte

85 Lymphomatoid granulomatosis has a high rate of central nervous system

86 of systematic vasculitis, such as Wegener's granulomatosis, have circulating antineutrophil cytoplas

87 y; for example, most patients with Wegener's granulomatosis in China have myeloperoxidase-antineutrop

88 Other genes associated with Wegener's granulomatosis in replicated candidate gene studies are

89 The prevalence of Wegener's granulomatosis in the United States is approximately 3.0

90 olyangiitis (P = 2.9 x 10(-4)) and Wegener's granulomatosis in two independent cohorts from the UK (P

91 have systemic lupus erythematosus, Wegener's granulomatosis, inflammatory myopathy, or polyarteritis

92 Wegener's granulomatosis is a multisystem disease characterized by

93 Lymphomatoid granulomatosis is a rare Epstein-Barr virus-associated B

94 ), the major target autoantigen in Wegener's granulomatosis is a serine proteinase that is normally s

95 evidence supports the notion that Wegener's granulomatosis is an autoimmune disease.

96 Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity and

97 The incidence rate of VTEs in Wegener granulomatosis is high when compared with available rate

98 we hypothesised that low-grade lymphomatoid granulomatosis is immune-dependent and high-grade lympho

99 immune-dependent and high-grade lymphomatoid granulomatosis is immune-independent.

100 racteristic granuloma formation of Wegener's granulomatosis is unclear.

101 matosis with polyangiitis (GPA; or Wegener's granulomatosis) is the granulomatous inflammation of the

102 f clinical entities referred to as "familial granulomatosis." It is the sole human model with recogni

103 tis, systemic lupus erythematosis, Wegener's granulomatosis, juvenile dermatomyositis, juvenile scler

104 virus (EBV) infection, such as lymphomatoid granulomatosis (LG) or post-transplant lymphoproliferati

105 Thyroid disease, breast disease and granulomatosis lung disease were the most frequent cause

106 Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-

107 Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus-associ

108 Lymphomatoid granulomatosis (LyG) is an angiodestructive lymphoprolif

109 subset of vasculitis that includes Wegener's granulomatosis, microscopic polyangiitis (microscopic po

110 uses of orbital inflammation such as Wegener granulomatosis must be considered to prevent potentially

111 microscopic polyangiitis (n=43) or Wegener's granulomatosis (n=42).

112 and neck is most commonly caused by Wegener granulomatosis, natural killer/T-cell lymphomas, cocaine

113 Orofacial granulomatosis (OFG) is characterized by granulomatous i

114 le patients had newly diagnosed AAV (Wegener granulomatosis or microscopic polyangiitis) and were age

115 ANCA-positive patients with either Wegener's granulomatosis or microscopic polyangiitis.

116 diseases such as Crohn's disease, Wegener's granulomatosis, or sarcoidosis.

117 1990 ACR classification criteria for Wegener granulomatosis, polyarteritis nodosa, giant-cell arterit

118 vary considerably in patients with Wegener's granulomatosis, polyarteritis nodosa, microscopic polyan

119 tis, systemic lupus erythematosus, Wegener's granulomatosis, polymyositis, dermatomyositis, polyarter

120 A 56-year-old man with a history of Wegener granulomatosis presented with 6 days of sinus congestion

121 uide the management of patients with Wegener granulomatosis remains controversial.

122 ith polyangiitis (GPA), previously Wegener's granulomatosis, requires prompt diagnosis and systemic r

123 hereas patients with high-grade lymphomatoid granulomatosis showed expected responses to chemotherapy

124 Within the Wegener's granulomatosis subgroup, the median VDI score for 12 non

125 inase 3 and neutrophil elastase in Wegener's granulomatosis, support the concept that there is a natu

126 a biopsy-confirmed diagnosis of lymphomatoid granulomatosis that evolved into fatal B-cell lymphoma o

127 asculitides is wide: For example, in Wegener granulomatosis the pattern ranges from cavitating nodule

128 In particular, in contrast to Wegener's granulomatosis, the need for routine cyclophosphamide tr

129 italizations/year in patients with Wegener's granulomatosis to 2 cases/10,000 hospitalizations/year i

130 Patients with Wegener's granulomatosis usually seek medical care for respiratory

131 incidence of VTE among patients with Wegener granulomatosis was 7.0 per 100 person-years (95% CI, 4.0

132 A diagnosis of Wegener's granulomatosis was considered in all of them, but abando

133 Wegener's granulomatosis was initially considered to be most likel

134 ies of the use of plasma exchange in Wegener granulomatosis was published.

135 An exacerbation of Wegener granulomatosis was the principal concern because of the

136 s with pathologically confirmed lymphomatoid granulomatosis were enrolled in a natural history and tr

137 Patients with Wegener's granulomatosis were excluded.

138 Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) h

139 for the small vessel vasculitides Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA).

140 Wegener's granulomatosis (WG) is a granulomatous vasculitis that a

141 Wegener's granulomatosis (WG) is a systemic inflammatory disease t

142 Wegener's granulomatosis (WG) is a systemic vasculitis of unknown

143 ecipitating event(s) that triggers Wegener's granulomatosis (WG) is unknown.

144 describes a case of severe limited Wegener's granulomatosis (WG) presenting in the third trimester of

145 chronic hepatitis C infection, and Wegener's granulomatosis (WG), an inflammatory, granulomatous vasc

146 he neutrophilic vasculitis seen in Wegener's granulomatosis (WG), are directed against proteinase-3 (

147 cytoplasmic antibodies (ANCAs) in Wegener's granulomatosis (WG).

148 lasmic antibody (cANCA)-associated Wegener's granulomatosis (WG).

149 approximately 60% of patients with Wegener's granulomatosis (WG).

150 a determinant of susceptibility to Wegener's granulomatosis (WG).

151 She was initially thought to have Wegener's granulomatosis (WG).

152 h CIMDL with that in patients with Wegener's granulomatosis (WG).

153 Total PSV, subgroups (47 Wegener's granulomatosis [WG], 12 microscopic polyangiitis, 16 Chu

154 y with Rheumatoid Arthritis (aHR = 0.22), or Granulomatosis with Polyangiitis (aHR = 0.08).

155 ically with Rheumatoid Arthritis (aHR=0.64), Granulomatosis with Polyangiitis (aHR=0.21), or Systemic

156 hils or Th2 immune responses in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome

157 on the beneficial use of RTX in eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

158 Eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA) i

159 oscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA),

160 yndrome (HES) disease including eosinophilic granulomatosis with polyangiitis (EGPA) accounted for 85

161 f placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) achieved protoco

162 mmunologic mechanisms promoting eosinophilic granulomatosis with polyangiitis (EGPA) are unclear.

163 Eosinophilic granulomatosis with polyangiitis (EGPA) is a disease wit

164 Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-n

165 Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflam

166 Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare system

167 Eosinophilic granulomatosis with polyangiitis (eGPA) is a small-vesse

168 Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic va

169 Eosinophilic granulomatosis with polyangiitis (EGPA) is a type of ANC

170 Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis

171 pereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and eosinophili

172 roscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), that share feat

173 roscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).

174 is with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

175 oscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

176 oneuritis (MM) in patients with eosinophilic granulomatosis with polyangiitis (EGPA).

177 oscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-S

178 condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wege

179 the subsequent activation of neutrophils in granulomatosis with polyangiitis (formerly Wegener disea

180 isease (IgG4-ROD) (5 scans, 3 patients), and granulomatosis with polyangiitis (GPA) (3 scans, 1 patie

181 erence (CHCC) definition with categories for granulomatosis with polyangiitis (GPA) (Wegener's), micr

182 Lacrimal gland involvement in granulomatosis with polyangiitis (GPA) commonly accompan

183 Ocular manifestations of granulomatosis with polyangiitis (GPA) have been reporte

184 Granulomatosis with polyangiitis (GPA) is a potentially

185 Granulomatosis with polyangiitis (GPA) is a rare, aggres

186 Granulomatosis with polyangiitis (GPA) is a systemic nec

187 Granulomatosis with polyangiitis (GPA) is an antineutrop

188 Granulomatosis with polyangiitis (GPA) is an uncommon au

189 intestinal manifestations in ANCA-associated granulomatosis with polyangiitis (GPA) may be present, h

190 Granulomatosis with polyangiitis (GPA) represented the h

191 ry including microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic

192 The three AAV subgroups, namely granulomatosis with polyangiitis (GPA), microscopic poly

193 (ANCA)-associated vasculitis (AAV) comprises granulomatosis with polyangiitis (GPA), microscopic poly

194 passes three rare yet interrelated diseases: granulomatosis with polyangiitis (GPA), microscopic poly

195 erns of lung disease mirroring patients with granulomatosis with polyangiitis (GPA), microscopic poly

196 Granulomatosis with polyangiitis (GPA), previously Wegen

197 enotypes, microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), share similariti

198 ti-PR3 (338 U/mL), confirming a diagnosis of granulomatosis with polyangiitis (GPA).

199 er treatment having a specific advantage for granulomatosis with polyangiitis (GPA).

200 ic bronchopulmonary aspergillosis (ABPA) and granulomatosis with polyangiitis (GPA).

201 injury during autoimmune vasculitis, such as granulomatosis with polyangiitis (GPA).

202 The ANCA-associated vasculitides, granulomatosis with polyangiitis (GPA, formerly Wegener'

203 replicate the granulomatous lesions found in granulomatosis with polyangiitis (GPA, formerly Wegener'

204 es in development of systemic vasculitis and granulomatosis with polyangiitis (GPA, Wegener's granulo

205 A key feature of granulomatosis with polyangiitis (GPA; or Wegener's gran

206 remission in patients with chronic relapsing granulomatosis with polyangiitis (Wegener's) (GPA).

207 ve been repeatedly reported in patients with granulomatosis with polyangiitis (Wegener's) (GPA).

208 ial (WGET), which included 180 patients with granulomatosis with polyangiitis (Wegener's) (GPA).

209 Granulomatosis with polyangiitis (Wegener's) is a rare a

210 tanding the pathogenesis and presentation of granulomatosis with polyangiitis (Wegener's).

211 the use of rituximab (RTX) in patients with granulomatosis with polyangiitis (Wegener's; GPA), micro

212 sease [IgG4RD] or ANCA-negative eosinophilic granulomatosis with polyangiitis [EGPA] overlaps).

213 of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis and hypereosinophilic s

214 ed vasculitis consists of two main diseases, granulomatosis with polyangiitis and microscopic polyang

215 Granulomatosis with polyangiitis and microscopic polyang

216 omponent, shows genetic distinctions between granulomatosis with polyangiitis and microscopic polyang

217 ith ANCA-associated vasculitis and also that granulomatosis with polyangiitis and microscopic polyang

218 In contrast, neutrophils from patients with granulomatosis with polyangiitis expressing high membran

219 t 11 of 37 (30%) females in the eosinophilic granulomatosis with polyangiitis group (p < .04).

220 Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasc

221 was stratified by ANCA type, AAV diagnosis (granulomatosis with polyangiitis versus microscopic poly

222 ts with relapsing or refractory eosinophilic granulomatosis with polyangiitis who had received treatm

223 The 115 enrolled patients (87 with granulomatosis with polyangiitis, 23 with microscopic po

224 e target of anti-neutrophil cytoplasm Abs in granulomatosis with polyangiitis, a form of systemic vas

225 hn's disease, Behcet's disease, eosinophilic granulomatosis with polyangiitis, and immunoglobulin A (

226 iant cells are key pathological hallmarks of granulomatosis with polyangiitis, but are absent in micr

227 We describe a 15-year-old girl with granulomatosis with polyangiitis, formerly known as Wege

228 Proteinase 3 (PR3), the autoantigen in granulomatosis with polyangiitis, is expressed at the pl

229 In participants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted i

230 id arthritis, chronic lymphocytic leukaemia, granulomatosis with polyangiitis, microscopic polyangiit

231 Patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiit

232 ression of PR3 is increased in patients with granulomatosis with polyangiitis, MVs generated from neu

233 temic diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, Sjogren's syndrome, sa

234 th EM were hypersensitivity and eosinophilic granulomatosis with polyangiitis, which accounted for 34

235 have value in the treatment of eosinophilic granulomatosis with polyangiitis.

236 isease, nonspecific orbital inflammation, or granulomatosis with polyangiitis.

237 gers, and clearers of the PR3 autoantigen in granulomatosis with polyangiitis.

238 3 anti-neutrophil cytoplasmic antibodies) in granulomatosis with polyangiitis.

239 underlying systemic condition, most commonly granulomatosis with polyangiitis; however, bilaterality

240 Finally, plasma exchange for Wegener granulomatosis with severe renal dysfunction appears not